

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:488156-2019:TEXT:EN:HTML>

**United Kingdom-Runcorn: Vaccines  
2019/S 201-488156**

**Contract award notice**

**Results of the procurement procedure**

**Supplies**

**Legal Basis:**

Directive 2014/24/EU

**Section I: Contracting authority**

**I.1) Name and addresses**

The Secretary of State for Health and Social Care acting as part of the Crown through the Department of Health and Social Care  
2nd Floor, Rutland House  
Runcorn  
WA7 2ES  
United Kingdom  
E-mail: [Lynne.Nichols@dhsc.gov.uk](mailto:Lynne.Nichols@dhsc.gov.uk)  
NUTS code: UK

**Internet address(es):**

Main address: <https://dh.bravosolution.co.uk>

**I.2) Information about joint procurement**

The contract is awarded by a central purchasing body

**I.4) Type of the contracting authority**

Ministry or any other national or federal authority, including their regional or local subdivisions

**I.5) Main activity**

Health

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title:**

Contract for Supply of Hib-Men C Vaccine  
Reference number: CM/PHV/19/501

**II.1.2) Main CPV code**

33651600

**II.1.3) Type of contract**

Supplies

**II.1.4) Short description:**

Contract for the supply of haemophilus influenza type B, meningococcal C vaccine (Hib/Men C)

**II.1.6) Information about lots**

This contract is divided into lots: no

II.1.7) **Total value of the procurement (excluding VAT)**

Value excluding VAT: 1.00 GBP

II.2) **Description**

II.2.1) **Title:**

II.2.2) **Additional CPV code(s)**

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Bedford, UK.

II.2.4) **Description of the procurement:**

The provision of a vaccine to protect against Haemophilus influenzae type B (Hib) and meningitis C (MenC), to be used in the national childhood immunisation programme.

The contracting authority estimates their requirement over the period of the contract to be up to 3 000 000 doses.

Deliveries will be required over a period of 2 years.

II.2.5) **Award criteria**

Quality criterion - Name: Available on request / Weighting: Not applicable

Cost criterion - Name: Available on request / Weighting: Not applicable

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Value — this information is considered by the supplier to be commercially sensitive information. The authority is not publishing the value so as not to prejudice the legitimate commercial interests of the supplier.

**Section IV: Procedure**

IV.1) **Description**

IV.1.1) **Type of procedure**

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below

- The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the directive
- The works, supplies or services can be provided only by a particular economic operator for the following reason:
  - absence of competition for technical reasons

Explanation:

There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2015.

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

IV.1.6) **Information about electronic auction**

**IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

**IV.2) Administrative information**

**IV.2.1) Previous publication concerning this procedure**

Notice number in the OJ S: [2019/S 187-454780](#)

**IV.2.8) Information about termination of dynamic purchasing system**

**IV.2.9) Information about termination of call for competition in the form of a prior information notice**

**Section V: Award of contract**

A contract/lot is awarded: yes

**V.2) Award of contract**

**V.2.1) Date of conclusion of the contract:**

08/10/2019

**V.2.2) Information about tenders**

Number of tenders received: 1

Number of tenders received by electronic means: 1

The contract has been awarded to a group of economic operators: no

**V.2.3) Name and address of the contractor**

GlaxoSmithkline UK Ltd

Brentford

United Kingdom

NUTS code: UKI75

The contractor is an SME: no

**V.2.4) Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 1.00 GBP

**V.2.5) Information about subcontracting**

**Section VI: Complementary information**

**VI.3) Additional information:**

The contract(s) is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract(s) may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes.

**VI.4) Procedures for review**

**VI.4.1) Review body**

The High Court

Strand

London

WC2A 2LL

United Kingdom

**VI.4.2) Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**  
15/10/2019